If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Mounjaro® (tirzepatide) be used in patients with hypothyroidism or hyperthyroidism?
Lilly has not conducted a study to evaluate the safety and efficacy of tirzepatide in patients with hypothyroidism or hyperthyroidism.
See important safety information, including boxed warning, in the attached prescribing information.
Use in Patients With Hypothyroidism or Hyperthyroidism
There is no information on the use of tirzepatide in people with hypothyroidism or hyperthyroidism because this has not been studied.
People with controlled endocrine disorders could participate in the tirzepatide studies for type 2 diabetes. However, they were excluded from these studies if they had a significant, uncontrolled endocrine disorder (eg, thyrotoxicosis or adrenal crises) in the opinion of the investigator.1
Enclosed Prescribing Information
Reference
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: October 06, 2023